Inactive

PRE-SOLICITATION NOTICE OF INTENT NON-COMPETITIVE Notice of Intent: 75N95022Q00530 INTRODUCTION PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE- SOLICITATION NOTICE OF... PRE-SOLICITATION NOTICE OF INTENT NON-COMPETITIVE Notice of Intent: 75N95022Q00530 INTRODUCTION PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE- SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION. THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisitions, Contracts Management t Blue, NCATS Section on behalf of the National Center for Advancing Translational Sciences intends to negotiate and award a contract for 108 unique spirocyclic compounds to VWR International, LLC, 100 Matsonford Rd. Bldg. 1, Suite 200, Radnor, PA 19087-4569. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS Code 325412: Pharmaceutical Preparation Manufacturing with a Size Standard of 1,250. Set-aside Status: Small Business set-aside restriction is not applicable. Competition Status: This requirement is posted as non-competitive. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses of the Federal acquisition Regulation (FAR) in effect through the Federal Acquisition Circular 2022-06, dated May 26, 2022. STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source. DESCRIPTION OF REQUIREMENT The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), which mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The Early Translational Branch (ETB) is tasked with identifying and developing novel small molecule leads against a wide spectrum of human disease targets, which it accomplishes by screening thousands of small molecules in collaboration with both intra-and extramural researchers. In pursuit of this goal, the Center has a strong internal trans-disciplinary team of scientists who continually discover novel small molecules to modulate non-opioid molecular targets to treat pain and addiction. As such, discovering lead molecules that could serve as starting points for therapeutic development for patients is a key part of discovery. Therefore, it is important to explore novel chemical space during chemistry optimization and tweak the potency and property of the molecules. The optimized test compounds should modulate on-target activity and avoid any toxicity before advancing the compound for efficacy studies in animals which requires the utilization of unique chemical building blocks. The outcomes will be used to assess the therapeutic potential of lead compounds against novel biological spaces which are safer alternatives for opioid targets. The current acquisition is essential for multiple projects within ETB. 108 unique spirocyclic building block sets selected using a manual selection process of for identifying unique building blocks available in the commercial place which is listed below by (Avantor by VWR). SPK1d-100 (6 compounds) Cust-SPK1f-100 (7 compounds) Cust-SPK1g-100 (3 compounds) Cust-SPK1h- 100 (4 compounds) Cust-SPK1j-100 (5 compounds) Cust-SPK1-100 (5 compounds) SPK2a-100 (9 compounds) SPK2b-250 (7 compounds) SPK2c-250 (8 compounds) SPK2d-250 (9 compounds) SPK3a-100 (11 compounds) SPK3c-100 (13 compounds) SPK3d-100 (10 compounds) SPK3e-100 (8 compounds) Cust-SPK4c-100 (3 compounds) All the compounds should be provided in the specified quantities with >95 % purity as specified by NMR and LCMS or MS characterization techniques. The whole set needs to be synthesized at the same vendor and shipped as one package to avoid any inconsistency. General Requirements Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified, personnel, material, equipment, and facilities not otherwise provided by the Government as needed to perform the Specific Requirements below: Purchase Description See Attached Period of Performance Four weeks ARO CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. The respondents must submit clear and convincing evidence that their product is equivalent or superior to the product specified in this notice. The response shall include: the unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered to determine the method of acquisition. The response must also indicate the country of manufacturer of components and country of assembly (not necessary for IT and Maintenance purchases). A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non- competitive basis or to conduct a competitive procurement. All responses must be received by August 24, 2022 at 3:00 PM Eastern Time and must reference number 75N95022Q00530. Responses must be submitted electronically to Michelle Cecilia, Contracting Officer, at michelle.cecilia@nih.gov, and must reference the solicitation number 75N95022Q00530 on your electronic request. FAX requests are not accepted. “All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.”